Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.
The booming weight-loss drug market is being led by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The last 2 weeks have seen Zepbound just edge past Wegovy in the number of prescriptions made in the US, as well as a major partnership announcement with Amazon.com.
Amazon.com’s pharmacy unity will deliver drug prescriptions of Zepbound made through Eli Lilly’s direct-to-consumer service LillyDirect. LillyDirect was launched in January 2024 to enable access to migraine, diabetes, and obesity drugs for patients directly from the company via online pharmacy Truepill. With the Amazon.com partnership, prescriptions made to LillyDirect will now either be filled and delivered by Amazon Pharmacy or Truepill. Orders will be split between the two companies.
Surging demand for weight-loss drugs such as Zepbound and Wegovy was the impetus for LillyDirect launching. The market is expected to reach US$100 billion by the end of the 2020s. A spokesperson for the drugmaker states that they “looked forward to continuing to enhance LillyDirect with additional medicines, partners, and service providers in the near future.”
The demand for weight-loss drug products does not seem to be slowing any time soon – on March 15, data from IQVIA revealed that new prescriptions for Zepbound reached over 77,000 in the US. This would be the first time prescriptions for Zepbound have surpassed Wegovy since their respective launches. Zepbound launched in the US in December 2023, over 2 years after Wegovy’s approval.
Earlier this month, Wegovy was approved in the US for the indication of reducing risk of strokes and heart attacks in overweight or obese adults. Eli Lilly also produces the diabetes drug Mounjaro, which contains the same API as Zepbound. Mounjaro is forecasted by GlobalData to be the top-selling GLP-1 product by 2029.
Sources:
1. Lilly partners with Amazon to deliver Zepbound and other drugs [Accessed March 19, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-weight-loss-drug-zepbound-new-us-prescriptions-surpass-wegovy-first-time-2024-03-15/
2. Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time [Accessed March 19, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-weight-loss-drug-zepbound-new-us-prescriptions-surpass-wegovy-first-time-2024-03-15/
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
.png)
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance